Improvement in Safety Monitoring of Biologic Response Modifiers After the Implementation of Clinical Care Guidelines by a Specialty Pharmacy Service in an Academic Health System

BACKGROUND: Tumor necrosis factor (TNF)-alpha inhibitors and other biologic response modifiers (BRMs) are frequently used to treat a variety of inflammatory diseases. Use of these agents may increase risk of serious infections, malignancies, and other complications such as worsening symptoms of hear...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanson, Rebekah L., Gannon, Michael J., Khamo, Nehrin, Sodhi, Monsheel, Orr, Alexander M., Stubbings, JoAnn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2013
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437345/
https://www.ncbi.nlm.nih.gov/pubmed/23383700
http://dx.doi.org/10.18553/jmcp.2013.19.1.49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437345/
https://www.ncbi.nlm.nih.gov/pubmed/23383700
http://dx.doi.org/10.18553/jmcp.2013.19.1.49

Ejemplares similares